Bullous Pemphigoid
Bullous Pemphigoid is a rare autoimmune skin disorder characterized by large, fluid-filled blisters that can be itchy and painful, typically occurring on areas of the skin that flex, such as the arms and legs.
Immunological Diseases: RAY121 Treatment
We are testing RAY121 for people with various immunological diseases to see if it can help manage their condition by inhibiting the immune response.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Immune-Mediated Necrotizing Myopathy
Immune-Mediated Necrotizing Myopathy is a rare muscle disease that leads to muscle weakness and damage due to an autoimmune response, often affecting the proximal muscles.
Dermatomyositis
Dermatomyositis is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash, often affecting the face, neck, and back.
Immune Thrombocytopenia
Immune Thrombocytopenia is a rare blood disorder where the immune system mistakenly attacks and destroys platelets, leading to easy bruising and bleeding.
Antiphospholipid Syndrome
Antiphospholipid Syndrome is a rare autoimmune disorder that increases the risk of blood clots due to the presence of antiphospholipid antibodies in the body.
Behçet’s Syndrome
Behçet’s Syndrome is a rare autoimmune condition that causes inflammation in blood vessels, leading to symptoms like mouth and genital ulcers, skin lesions, and eye inflammation.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medical University Of Vienna
Department of Clinical Pharmacology
Vienna, Austria
Umbal - Prof. D-R Stoyan Kirkovich AD
Department of Clinical Hematology
Kardzhali, Bulgaria
Specialized Hospital For Active Treatment Of Hematological Diseases EAD
Clinic of Clinical Hematology
Sofia, Bulgaria
Sponsor: Chugai Pharmaceutical Co. Ltd.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.